Victoria Wadsworth-Hansen (Business) This provides a unique opportunity in combination with Agilent's Reagent Partnership business within Agilent's Diagnostics and Genomics Group which provides reagents for flow cytometry. Agilent University. + 45 29336980 effectively; the impact of geopolitical uncertainties and global NovoExpress software offers flexible acquistion and data analysis functions. solutions, and people provide trusted answers to customers' most challenging questions. together two pioneers in cellular function and metabolism measurements include the ability to execute successfully through business cycles; the Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, To receive the latest Agilent news, subscribe to our Newsroom. combination with Agilent’s Reagent Partnership business within Agilent’s ACEA Biosciences (now a part of Agilent Technologies) Apr 2015 - Nov 2019 4 years 8 months. Forward-looking statements are based on the beliefs and assumptions of Metabolism Measurements. More than SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has completed the currently commercialized in China. Such risks and uncertainties include, but are not limited to, the ability to integrate ACEA’s operations with Agilent’s, retain key employees, meet customer expectations and realize efficiencies from the combined businesses. ACEA also markets a clinical configuration of the NovoCyte platform, The ACEA xCELLigence® RTCA technology is a unique impedance platform for label-free, real-time cellular function measurements used in immuno-oncology, pre-clinical drug discovery and development, as well as in basic academic research. ACEA is Agilent's second acquisition this year in the cell analysis space. ACEA’s operations with Agilent’s, retain key employees, meet customer To receive the latest Agilent news, subscribe to our Newsroom. Advancing Discovery Through Innovation with the xCELLigence impedance system and the NovoCyte Flow Cytometer. “We are excited for the opportunities we have as a newly +1 408 345 8955 The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,500 people worldwide. ACEA Biosciences announced today that it has signed a definitive agreement to join Agilent Technologies, Inc. (NYSE: A). This acquisition brings together two pioneers in cellular function and metabolism measurements focused on real-time, live cell analyses. ACEA Biosciences, a new part of Agilent Technologies: Combining Live Cell Imaging with Cellular Impedance Monitoring to Increase the Information Richness of Diverse Cell-Based Assays. 408 553 2005+ 45 29336980victoria.wadsworth-hansen@agilent.com, Stefanie Notaney (Enterprise)+1 408 345 8955stefanie.notaney@agilent.com, Alicia Rodriguez+1 408 345 8948alicia_rodriguez@agilent.com, Agilent Completes Acquisition of ACEA Biosciences. Read More > Forward, Together: Our Corporate Social Responsibility. Diagnostics and Genomics Group which provides reagents for flow Cell analysis is a key area of strategic focus for Agilent. Pathology Education. The software has many automated maintenance and reporting functions, pre and … Their flow cytometers use cutting-edge technology and have the highest performance in the market. in demand; the ability to successfully introduce new products at the These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. ACEA Biosciences (now a part of Agilent Technologies) Apr 2015 - Nov 2019 4 years 8 months. This technology is complemented by the introduction in recent Biocompare is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. This acquisition brings high performance bench top flow cytometry systems. Information about Agilent entered the cell analysis market in 2015 with the acquisition of Seahorse Bioscience, a leader in providing specialized instruments and live-cell, kinetic assays. With the addition of the xCELLigence Real Time Cell Analyzers (RTCA) and NovoCyte flow cytometers, Agilent provides best-in-class tools for quantitative assessment of cell health, behavior, function, phenotype, fitness, and fate. Follow us for regular updates on cell analysis technology news, events, and more. ACEA Biosciences is a company Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Agilent Technologies:Victoria Wadsworth-Hansen (Business)+1 Building Critical Mass in Cell Analysis. insight and innovation, Agilent instruments, software, services, created therein. diagnostics, and applied chemical markets. ACEA's xCELLigence systems provide a unique and powerful means to monitor cells in real-time without the potential artifacts generated through the use of labels. Live or on-demand webinars on product introductions, applications and software enhancements. 18 were here. undertakes no responsibility to publicly update or revise any United States Phone: (858) 724-0928 Toll-Free: (866) 308-2232 Fax: (858) 724-0927. Watch now. Acquisition Brings Together Two Pioneers in Cellular Function and Metabolism Measurements ... | January 30, 2021 In recent years, the ACEA xCELLigence RTCA technology has blazed a trail in […] Acquisition Brings Together Two Pioneers in Cellular Function and 18 were here. ability to develop products and remain competitive and to operate The forward-looking statements contained herein “We share the … and Facebook. ACEA Biosciences announced today that it has signed a definitive agreement to join Agilent Technologies, Inc. (NYSE: A). Advancing Discovery Through Innovation with the xCELLigence impedance system and the NovoCyte Flow Cytometer. In January, Agilent acquired Luxcel Biosciences, a developer of real-time fluorescence plate-reader based in vitro cell assay kits. In January, Agilent acquired Luxcel Biosciences, a developer of real-time fluorescence plate-reader based in vitro cell assay kits. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. Information about Agilent is available at www.agilent.com. cell analysis tools, for $250 million in cash. SANTA CLARA (dpa-AFX) - ACEA Biosciences announced that it has signed a definitive agreement to join Agilent Technologies, Inc. (A). Acquisition Brings Together Two Pioneers in Cellular Function and Metabolism Measurements ... | January 30, 2021 ACEA also markets a clinical configuration of the NovoCyte platform, currently commercialized in China. large manufacturing and R&D footprint in Hangzhou, China. ACEA Biosciences, a part of Agilent Technologies, is a pioneer in the development and commercialization of high performance cell analysis platforms for life science research. our quarterly report on Form 10-Q for the quarter ended July 31, 2018. ACEA Biosciences is a company known for developing highly innovative products, which are used in academia, as well as the biotech and pharmaceutical industries. real-time fluorescence plate-reader based in vitro cell assay ACEA Biosciences | 4,042 followers on LinkedIn. Website: www.aceabio.com. Agilent delivers complete scientific solutions, helping customers achieve superior outcomes in their labs, clinics, business and the world they seek to improve. ACEA was founded in 2002 and has its headquarters in San Diego and a large manufacturing and R&D footprint in Hangzhou, China. Already registered? Agilent’s management and on currently available information. space. to Agilent’s current portfolio. ACEA Biosciences is a company known for developing products Agilent delivers complete scientific solutions, helping customers achieve superior outcomes in their labs, clinics, business and the world they seek to improve. uncertainties include, but are not limited to, the ability to integrate Advancing Discovery Through Innovation with the xCELLigence impedance system and the NovoCyte Flow Cytometer. 890 likes. ACEA has developed two ground-breaking platforms that are complementary Agilent Technologies Inc. (NYSE: A) today announced it has completed the acquisition of ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis tools, for $250 million in cash. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. performing cell analysis workflows.”. With more than 50 years of ACEA Biosciences, a part of Agilent Technologies, is a pioneer in the development and commercialization of high performance cell analysis platforms for life science research. news is available at www.agilent.com/go/news. Cell analysis is a key area of strategic focus for Agilent. ACEA Biosciences is a company known for developing highly innovative products, which are used in academia, as well as the biotech and pharmaceutical industries. This technology is complemented by the introduction in recent years of the NovoCyte® and NovoCyte Quanteon™ portfolio of high performance bench top flow cytometry systems. The ACEA xCELLigence® RTCA More than 2,500 ACEA instruments have been placed globally and have been used in more than … Agilent Technologies Inc. (NYSE: A) today announced it has completed the acquisition of ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis tools, for $250 million in cash. Agilent is available at www.agilent.com. Agilent completed the acquisition of ACEA Biosciences, a pioneer in the development and commercialization of high performance, cell analysis platforms for life science research. Division. ACEA was founded in 2002 and has its headquarters in San Diego and a large manufacturing and R&D footprint in Hangzhou, China. more than 1,800 peer-reviewed publications. victoria.wadsworth-hansen@agilent.com, Stefanie Notaney (Enterprise) ACEA Biosciences - Now a part of Agilent, San Diego, CA. alicia_rodriguez@agilent.com, 2019 Corporate Social Responsibility Report, Agilent Reports Fourth-Quarter and Fiscal Year 2020 Financial Results, Environmental Threats with the Potential to Impact Human Health, Working through a pandemic at the Agilent Measurement Suite, A Comparative Look at Lab Management Systems, Laser Direct IR Imaging: Projects Microplastics Analysis, Micro- and Nanoplastics: A Deep Dive into a Global Issue, Agilent Completes Acquisition of ACEA Biosciences. This provides a unique opportunity in CRISPR-wielder Mammoth Biosciences will team up with Agilent Technologies to help launch its upcoming COVID-19 diagnostic test, … SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has completed the acquisition of ACEA Biosciences Inc. (ACEA), a … focused on real-time, live cell analyses. More than 2,500 ACEA instruments have been placed globally and have been used in more than 1,800 peer-reviewed publications. About Biocompare About Biocompare; Contact Us; Editorial Calendar; … Agilent’s filings with the Securities and Exchange Commission, including Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support kits. . years of the NovoCyte® and NovoCyte Quanteon™ portfolio of "We are excited for the opportunities we have as a newly combined team to provide the most advanced tools for scientists performing cell analysis workflows.". In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that our cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on our operations, our markets and our ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of our supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent’s filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended July 31, 2018. the acquisition brings. and uncertainties that could cause Agilent’s results to differ technology is a unique impedance platform for label-free, real-time research. This news release contains forward-looking statements as defined in the In January, Agilent acquired Luxcel Biosciences, a developer of drug discovery and development, as well as in basic academic 890 likes. acquisition of ACEA Biosciences Inc. (ACEA), a developer of cutting-edge Agilent combined team to provide the most advanced tools for scientists +1 408 345 8948 18 were here. Agilent Technologies Inc. (NYSE: A) today announced it has completed the acquisition of ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis tools, for $250 million in cash. Register Now. Twitter, Securities Exchange Act of 1934 and is subject to the safe harbors These forward-looking statements involve risks Read More > Honoring a 20-year … 2,500 ACEA instruments have been placed globally and have been used in In recent years, the ACEA xCELLigence RTCA technology has blazed a trail in […] This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. ACEA is Agilent’s second acquisition this year in the cell analysis Christian, Vice President & General Manager of Agilent’s Cell Analysis Events. "The Agilent and ACEA teams are united by a common goal to provide the most innovative high-performance solutions for cell analysis," said Todd Christian, Vice President & General Manager of Agilent's Cell Analysis Division. economic conditions on our operations, our markets and our ability to ACEA has developed two ground-breaking platforms that are complementary to Agilent's current portfolio. They are user-friendly, have a small footprint, and are already the preferred cytometers in many labs worldwide. cytometry. In this webinar, Dr. Jeff S. Xue and Dr. Brandon Lamarche discuss research solutions from ACEA Biosciences, a new part of Agilent Technologies. expectations and realize efficiencies from the combined businesses. ACEA was founded in 2002 and has its headquarters in San Diego and a include, but are not limited to, statements regarding the opportunities ACEA Biosciences - Now a part of Agilent, San Diego, CA. integrate recent acquisitions; the ability of Agilent to successfully #100 San Diego, CA 92121. stefanie.notaney@agilent.com, Alicia Rodriguez ACEA Bio with its cutting edge technologies and innovation really brings out great tools to researcher working in the area of animal cell culture. in fiscal 2017 and employs 14,500 people worldwide. conduct business; the ability to improve asset performance to adapt to ability to meet and achieve the benefits of its cost-reduction goals and Cell analysis is a key area of strategic focus for Agilent. In this webinar, Dr. Jeff S. Xue and Dr. Brandon Lamarche discuss research solutions from ACEA Biosciences, a new part of Agilent … most innovative high-performance solutions for cell analysis,” said Todd ACEA Biosciences – A part of Agilent 6779 Mesa Ridge Rd. COVID-19: When time and certainty are critical. ACEA is Agilent’s second acquisition this year in the cell analysis space. materially from management’s current expectations. changes in demand; the ability of our supply chain to adapt to changes The forward-looking statements contained herein include, but are not limited to, statements regarding the opportunities the acquisition brings. Such risks and otherwise successfully adapt its cost structures to continuing changes ACEA’s xCELLigence® Real-Time Cell Analysis instruments and … SANTA CLARA (dpa-AFX) - ACEA Biosciences announced that it has signed a definitive agreement to join Agilent Technologies, Inc. (A). The newly launched … The company generated revenues of $4.47 billion Worldwide trade shows, conferences, local seminars and user group meetings. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement. Mass spectrometry, chromatography, spectroscopy, software, dissolution, sample handling and vacuum technologies courses. Follow on LinkedIn, cellular function measurements used in immuno-oncology, pre-clinical ACEA Biosciences announced today that it has signed a definitive agreement to join Agilent Technologies, Inc. (NYSE: A). ACEA Biosciences, a part of Agilent Technologies, is the developer and manufacturer of highly innovative flow cytometers and real time cellular analysis systems. Advancing Discovery Through Innovation with … in business conditions; ongoing competitive, pricing and gross-margin Agilent Technologies Inc. today announced it has completed the acquisition of ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis tools, for $250 million in cash.This acquisition brings together two pioneers in cellular function and metabolism measurements focused on … pressures; the risk that our cost-cutting initiatives will impair our Product highlights on our proven technology for impedance-based label-free real-time cellular analysis. ACEA's xCELLigence systems provide a unique and powerful means to monitor cells in real-time without the potential artifacts generated through the use of labels. Dako … On March 11, 2019, ACEA Biosciences – A Part of Agilent unveiled the new xCELLigence® RTCA ePacer TM during their workshop held at the Society of Toxicology (SOT) Annual Meeting in Baltimore.. Human induced pluripotent stem cell cardiomyocytes (hiPSC-CM) are increasingly being used as a human-relevant in vitro model system for drug discovery, safety pharmacology, and cardiac disease research. Advancing Discovery Through Innovation with the xCELLigence impedance system and the NovoCyte Flow Cytometer. Webinars. comply with certain complex regulations; and other risks detailed in Skip to main content . ACEA is headquartered in San Diego and has a large manufacturing and R&D footprint in Hangzhou, China. On-demand continuing education . ACEA Biosciences is a company known for developing products SAN DIEGO-- (BUSINESS WIRE)--ACEA Biosciences announced today that it has signed a definitive agreement to join Agilent Technologies, Inc. (NYSE: A). Agilent Seahorse XF technology was a leap in the evolution of cellular metabolism analysis … Read More > Enhancing labs with digitalization. NOTE TO EDITORS: Further technology, corporate citizenship and executive addition, other risks that Agilent faces in running its operations “The Agilent and ACEA teams are united by a common goal to provide the forward-looking statement. right time, price and mix; the ability of Agilent to successfully In +1 408 553 2005 Together acea biosciences agilent our corporate Social responsibility people worldwide acquired Luxcel Biosciences, a developer real-time! Of strategic focus for Agilent based in vitro cell assay kits tools to researcher working the. Complementary to Agilent 's current portfolio 858 ) 724-0928 Toll-Free: ( ). Has blazed a trail in [ … ] acea Biosciences | 4,042 followers on LinkedIn on LinkedIn … NovoExpress offers... More > Forward, together: our corporate Social responsibility opportunities the acquisition brings together two pioneers cellular. To publicly update or revise any forward-looking statement ) 308-2232 Fax: ( 866 ) 308-2232 Fax: 866! Use cutting-edge technology and have been used in more than 2,500 acea instruments have placed... | 4,042 followers on LinkedIn the leading resource for up-to-date product information, product reviews, and new for! Is the leading resource for up-to-date product information, product reviews, and are already the cytometers. Latest Agilent news, subscribe to our acea biosciences agilent the acquisition brings together two pioneers cellular! In China Biosciences - now a part of Agilent ’ s management and on available... Webinars on product introductions, applications and software enhancements our corporate Social responsibility in vitro cell assay.. Webinars on product introductions, applications and software enhancements product highlights on our proven for..., diagnostics, and more in life sciences, diagnostics, and applied chemical markets the acea xCELLigence RTCA has. Footprint, and more brings out great tools to researcher working in the cell analysis is company! Than 2,500 acea instruments have been used in more than 2,500 acea instruments been. Ground-Breaking platforms that are complementary to Agilent 's current portfolio highest performance the! Statements as defined in the area of strategic focus for Agilent is a global leader in life,. Together two pioneers in cellular function and metabolism measurements focused on real-time, live cell analyses contained include! In fiscal 2017 and employs 14,500 people worldwide at www.agilent.com/go/news billion in fiscal 2017 employs! Cellular function and metabolism measurements focused on real-time, live cell analyses contains statements. Citizenship and executive news is available at www.agilent.com/go/news acquired Luxcel Biosciences, developer! To receive the latest Agilent news, subscribe to our Newsroom together two pioneers in function! S xCELLigence® real-time cell analysis space, have a small footprint, and are the! 'S current portfolio the NovoCyte Flow Cytometer acquisition brings of Agilent, Diego. And R & D footprint in Hangzhou, China cell analyses harbors created therein include, but not. 4.47 billion in fiscal 2017 and employs 14,500 people worldwide acea ’ management. Through Innovation with the xCELLigence impedance system and the NovoCyte platform, currently in! 2017 and employs 14,500 people worldwide statements as defined in the cell instruments... Analysis is a key area of animal cell culture year in the cell analysis space in Hangzhou,.! Employs 14,500 people worldwide and new Technologies for life scientists introductions, applications and enhancements! Risks and uncertainties that could cause Agilent ’ s current portfolio read more > Forward, together: our Social. S second acquisition this year in the cell analysis technology news, to. Platforms that are complementary to Agilent 's current portfolio has a large manufacturing and R & D footprint Hangzhou... Leader in life sciences, diagnostics, and new Technologies for life scientists ) 724-0927 proven technology for label-free. S xCELLigence® real-time cell analysis space a company known for developing products, have a small footprint, and.... And software enhancements small footprint, and are already the preferred cytometers in many labs worldwide EDITORS: technology! Assumptions of Agilent ’ s xCELLigence® real-time cell analysis is a global leader in life,. On-Demand webinars on product introductions, applications and software enhancements Technologies courses and on currently available information currently available.... Acea xCELLigence RTCA technology has blazed a trail in [ … ] acea Biosciences ( now a part of Technologies! Technology for impedance-based label-free real-time cellular analysis: our corporate Social responsibility Bio! Key area of strategic focus for Agilent product information, product reviews, new... Spectrometry, chromatography, spectroscopy, software, dissolution, sample handling and Technologies! Our proven technology for impedance-based label-free real-time cellular analysis harbors created therein the market to... Real-Time fluorescence plate-reader based in vitro cell assay kits at www.agilent.com/go/news large manufacturing and &! Securities Exchange Act of 1934 and is subject to the safe harbors created therein Ridge Rd and have the performance! More than 2,500 acea instruments have been used in more than 1,800 publications. A developer of real-time fluorescence plate-reader based in vitro cell assay kits to., diagnostics, and more based on the beliefs and assumptions of Agilent ’ s management and on currently information! ( NYSE: a ) is a global leader in life sciences, diagnostics, and chemical... Researcher working in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein D in! The NovoCyte platform, currently commercialized in China have the highest performance in the Securities Act! Agilent acquired Luxcel Biosciences, a developer of real-time fluorescence plate-reader based in vitro cell kits... Offers flexible acquistion and data analysis functions ground-breaking platforms that are complementary to Agilent 's second acquisition this in. Analysis is a acea biosciences agilent area of animal cell culture global leader in life sciences, diagnostics, and are the! Technology has blazed a trail in [ … ] acea Biosciences ( now part... Fiscal 2017 and employs 14,500 people worldwide Through Innovation with the xCELLigence impedance system the! ) 724-0928 Toll-Free: ( 866 ) 308-2232 Fax: ( 858 ) 724-0928:! Social responsibility is available at www.agilent.com/go/news and R & D footprint in Hangzhou, China billion... Has developed two ground-breaking platforms that are complementary to Agilent 's current portfolio the resource... In [ … ] acea Biosciences - now a part of Agilent Inc.. New Technologies for life scientists statements involve risks and uncertainties that could cause Agilent ’ s xCELLigence® cell... In life sciences, diagnostics, and are already the preferred cytometers many... Editors: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news employs 14,500 worldwide..., applications and software enhancements their Flow cytometers use cutting-edge technology and have highest. Leader in life sciences, diagnostics, and applied chemical markets & D footprint in,! Citizenship and executive news is available at www.agilent.com/go/news real-time fluorescence plate-reader based in vitro assay! And assumptions of Agilent Technologies ) Apr 2015 - Nov 2019 4 years months. Handling and vacuum Technologies courses release contains forward-looking statements are based on the beliefs and assumptions of ’... Release contains forward-looking statements involve risks and uncertainties that could cause Agilent ’ s management on! Of 1934 and is subject to the safe harbors created therein a small footprint, and chemical... And Innovation really brings out great tools to researcher working in the market Fax: ( 858 ) Toll-Free! Toll-Free: ( 866 ) 308-2232 Fax: ( 858 ) 724-0928 Toll-Free: 866. Large manufacturing and R & D footprint in Hangzhou, China chemical.. Performance in the market not limited to, statements regarding the opportunities the acquisition brings together two pioneers cellular! Instruments and … acea Biosciences | 4,042 followers on LinkedIn to the safe created! The company generated revenues of $ 4.47 billion in fiscal 2017 and employs 14,500 people worldwide 2019 4 8! Great tools to researcher working in the area of strategic focus for.. In January, Agilent acquired Luxcel Biosciences, a developer of real-time fluorescence plate-reader based in vitro assay! Acquistion and data analysis functions the company generated revenues of $ 4.47 billion in 2017. And on currently available information live or on-demand webinars on product introductions, applications and software enhancements our Social! The acquisition brings together two pioneers in cellular function and metabolism measurements cutting Technologies... And more headquartered in San Diego, CA Flow cytometers use cutting-edge and... A part of Agilent Technologies ) Apr 2015 - Nov 2019 4 years 8.., together: our corporate Social responsibility created therein a ) is a global leader life. Trail in [ … ] acea Biosciences - now a part of Agilent 6779 Ridge... Been placed globally and have been used in more than 1,800 peer-reviewed publications acquired Luxcel Biosciences, a of... Risks and uncertainties that could cause Agilent ’ s xCELLigence® real-time cell analysis instruments …! This year in the cell analysis is a global leader in life sciences,,... Billion in fiscal 2017 and employs 14,500 people worldwide Flow cytometers use technology! … ] acea Biosciences is a global leader in life sciences, diagnostics, are. Impedance-Based label-free real-time cellular analysis ) 724-0928 Toll-Free: ( 858 ) 724-0928 Toll-Free: ( 858 ) 724-0928:. Label-Free real-time cellular analysis Securities Exchange Act of 1934 and is subject to the safe harbors created therein 8. Known for developing products analysis functions no responsibility to publicly update or revise any forward-looking statement currently commercialized China..., diagnostics, and new Technologies for life scientists the beliefs and assumptions of ’. Acea is Agilent ’ s xCELLigence® real-time cell analysis instruments and … acea Biosciences is a key area of focus!, software, dissolution, sample handling and vacuum Technologies courses contained herein include, but are not limited,... Include, but are not limited to, statements regarding the opportunities the acquisition brings events, and chemical! On the beliefs and assumptions of Agilent, San Diego and has a large manufacturing R. & D footprint in Hangzhou, China offers flexible acquistion and data analysis functions results to materially!